Condition: Fuchs Endothelial Corneal Dystrophy · Sponsor: Massachusetts Eye and Ear Infirmary
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
This description comes directly from the study's public registry record.
Michael Cheung, MSc, CCRP · 6175736060 · mcheung0@meei.harvard.edu
Ula Jurkunas, MD · 617-573-4330 · Ula_Jurkunas@meei.harvard.edu
Always discuss trial participation with your own doctor first.
| Massachusetts Eye and Ear Infirmary | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04440280